SIGNPATH PHARMA, INC.
🇺🇸United States
- Country
- 🇺🇸United States
- Ownership
- Private
- Established
- 2006-01-01
- Employees
- 2
- Market Cap
- -
Clinical Trials
3
Active:0
Completed:2
Trial Phases
1 Phases
Phase 1:3
Drug Approvals
0
Drug Approvals
No drug approvals found
This company may not have drug approvals in our database
Clinical Trials
Distribution across different clinical trial phases (3 trials with phase data)• Click on a phase to view related trials
Phase 1
3 (100.0%)Study of Liposomal Curcumin in Combination With RT and TMZ in Patients With Newly Diagnosed High-Grade Gliomas
Phase 1
Recruiting
- Conditions
- Glioblastoma
- Interventions
- Drug: Treatment Period 1Drug: Treatment Period 2Drug: Treatment Period 3Drug: Treatment Period 4a
- First Posted Date
- 2023-03-15
- Last Posted Date
- 2024-11-28
- Lead Sponsor
- SignPath Pharma, Inc.
- Target Recruit Count
- 30
- Registration Number
- NCT05768919
- Locations
- 🇺🇸
Sibley Memorial Hospital, Washington, District of Columbia, United States
🇺🇸Johns Hopkins University/Johns Hopkins Hospital, Baltimore, Maryland, United States
A Phase IB Dose Escalation Study of Lipocurc in Patients With Cancer
Phase 1
Completed
- Conditions
- Patients w/Advanced Cancer That Failed Std of Care Therapy
- Interventions
- First Posted Date
- 2014-05-15
- Last Posted Date
- 2022-05-11
- Lead Sponsor
- SignPath Pharma, Inc.
- Target Recruit Count
- 30
- Registration Number
- NCT02138955
- Locations
- 🇦🇹
3 Medicizinische Universitatsklinik Hematologie,Internistische Onkologie, Salzburg, Austria
🇦🇹3. Medizinische Universitatesclinik, Haematologie, Internistische Onkologie, Salzburg, Austria
Evaluation of Liposomal Curcumin in Healthy Volunteers
- First Posted Date
- 2011-07-27
- Last Posted Date
- 2014-05-26
- Lead Sponsor
- SignPath Pharma, Inc.
- Target Recruit Count
- 50
- Registration Number
- NCT01403545
- Locations
- 🇦🇹
Medical University of Vienna, Department of Clinical Pharmacology, Vienna, Austria
News
No news found